• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP
  • LOG IN
January 14, 2025 11:18 AM EST
News Briefing

Re­gen­eron, Il­lu­mi­na in­vest in Tru­ve­ta; In­hi­brx Bio’s $150M loan

ENDPOINTS

Plus, news about Biop­ti­mus, RhyGaze, Gri­fols, sub­cu­ta­neous Leqem­bi and Sling Ther­a­peu­tics:

Re­gen­eron pours $119.5M in­to Tru­ve­ta Se­ries C: Re­gen­eron will al­so work with the med­ical …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER

more like this

  • GLP-1s may cut can­cer risk; Gyre’s stock falls af­ter hep B da­ta and of­fer­ing May 23, 2025
  • Mod­er­na pulls ap­pli­ca­tion for Covid-flu shot; An­oth­er IPO in Hong Kong May 21, 2025
  • SV Health’s $269M de­men­tia fund; Schrödinger lays off 7% of staff May 20, 2025
TRENDING NOW

Trump asks 'very tough hom­bre' Dr. Oz to lead MFN talks

US warns drug­mak­ers against mis­rep­re­sent­ing cost of im­port­ed prod­ucts

About 5% of CBER and CDER left af­ter FDA staff cuts, analy­sis finds

Big leas­es, big­ger re­grets: Biotech slump turns swanky of­fices from as­set in­to li­a­bil­i­ty

Meet the ‘first sale’ rule: A cus­toms loop­hole phar­ma com­pa­nies could use to ease tar­iff im­pact

An­a­lyz­ing the End­points 100; ‘Most fa­vored na­tion’ tar­gets re­vealed; Biotech slump makes leas­es a li­a­bil­i­ty; and ...

Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times